Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype

Clinical trial NCT06486883 · RECRUITING

Trial details

NCT number: NCT06486883
Sponsor: MedSIR
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Advanced Breast Cancer Advanced Breast Carcinoma Hormone Receptor Positive Breast Carcinoma

Start date: 2025-06-30
Primary completion: 2027-01-01
Enrollment: 200

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.